Globus Medical, Inc. (GMED) Down 5.2% — Is This the Top?
Globus Medical, Inc. (GMED) is buckling under pressure this Friday, currently trading at $78.56 on the NYSE, a $4.35 decline from the prior close of $82.91. The drop extends a slide that has left the stock about 22.5% below its 52-week high of $101.40, set on January 8, 2026. A spine-surgery company that started the year near triple digits is now trading closer to the high $70s, and today's move adds to that gap.
Volume so far stands at 683,749 shares, against a 90-day average of roughly 1.52 million. With the regular session still open, turnover is running at less than half the typical full-day level.
Why Globus Medical, Inc. Price is Moving Lower
The most plausible driver is spillover from Stryker's sharp post-earnings selloff. Stryker Corporation (SYK) is down 6.02% today after its Q3 report on October 29 missed on both lines. Adjusted EPS came in at $3.52 against a $3.55 estimate, and revenue was $6.52 billion against $6.62 billion expected. Investors reacted more to the guidance. Stryker cut its 2026 organic sales-growth outlook to 6.5%–7.0% from 8.3%–9.3%, and it trimmed adjusted EPS guidance to $14.80–$14.90 from $14.95–$15.10. When the largest orthopedic franchise in the group lowers its growth forecast by that much, the market reprices the whole medical-device industry. Intuitive Surgical, Inc. (ISRG) is also down 3.07% today, so the selling extends beyond a single name.
This is a sector read-through rather than a Globus-specific problem. The company's own most recent results pointed the other way. For the second quarter, reported on August 6, Globus posted adjusted EPS of $1.34 against a $1.10 consensus. Revenue was $789.6 million against $782.8 million expected, up 5.9% year over year. GAAP net income fell 25.3% to $151.6 million, but that decline mostly reflects a $110.5 million Nevro acquisition gain in the prior-year quarter rather than weaker operations. Management raised 2026 adjusted-EPS guidance to $4.95–$5.05 and kept revenue guidance at $3.18 billion–$3.22 billion. On October 14, the company also showcased its FDA-cleared SCRIPT patient-specific implant platform and its XLIF Prone procedural solution, both additions to its spine portfolio.
Timing makes the Stryker read-through harder to dismiss. Globus reports Q3 results on November 5 after the market close, and investors have less than a week to decide whether the demand and execution concerns in Stryker's guidance will show up in Globus's numbers. Holders appear to be trimming exposure ahead of that report rather than waiting to find out, which is a rational response given the uncertainty.
What is the Globus Medical, Inc. Rating - Should I Sell?
Weiss Ratings assigns GMED a C+ rating. Current recommendation is Hold. The C+ sits at the upper end of the Hold range. It reflects a fundamentally sound business whose stock has not yet delivered the price stability or returns needed to justify a Buy, and today's sector-driven drop shows why caution remains appropriate.
The fundamental side of the profile is strong. The Excellent rating on the Growth Index is supported by 5.94% revenue growth and a raised adjusted-EPS outlook. That is a respectable pace for a spine and orthopedics company still integrating the large NuVasive and Nevro deals. The Solvency Index is also rated Excellent, a meaningful strength in a week when sector peers are cutting forecasts, because the balance sheet gives Globus room to absorb a softer demand environment. The Good rating on the Efficiency Index reflects a 17.02% profit margin and an 11.81% ROE. Those are healthy figures, but the ROE is held down by the equity base built through acquisitions, and that drag keeps the index short of Excellent.
Where the picture becomes more nuanced is the stock's performance. The Total Return Index is rated Fair, consistent with a share price about 22.5% below its January high despite earnings that beat expectations last quarter. The Weak Volatility Index is visible in today's session. A 5.25% drop driven by a competitor's guidance cut shows how exposed GMED remains to swings in sentiment across the device group, regardless of its own results. At a forward P/E of 21.26, the valuation does not leave much cushion if the November 5 report disappoints.
Within the Health Care sector, Globus Medical is on par with CVS Health Corporation (CVS, C+) and ahead of Stryker Corporation (SYK, C), Intuitive Surgical, Inc. (ISRG, C), and Abbott Laboratories (ABT, C). That edge over larger device peers is notable. However, a Hold is still a Hold, and the C+ rating calls for watchfulness rather than conviction.
About Globus Medical, Inc.
Globus Medical, Inc. (GMED) is a Health Care company focused on musculoskeletal solutions. Founded in 2003 and headquartered in Audubon, Pennsylvania, the company built its reputation on spinal implants. It has since expanded into trauma, joint reconstruction, and neuromodulation. Its 2023 merger with NuVasive substantially enlarged its spine franchise and brought in the XLIF lateral access approach. The Nevro acquisition added spinal cord stimulation technology for chronic pain.
Enabling technology is central to how Globus competes. Its ExcelsiusGPS robotic navigation platform, together with the broader Excelsius ecosystem of imaging and planning tools, ties surgeons and hospitals to Globus implants and instruments. That pull-through effect makes the installed robotic base a durable source of recurring procedure volume. More recent additions include the SCRIPT patient-specific implant platform, which tailors implants to individual anatomy, and the XLIF Prone solution, which adapts lateral spine access for patients positioned face-down.
The company sells mainly to hospitals and ambulatory surgery centers, in the United States and international markets. Its competitive advantages come from a broad spine portfolio, integrated robotics, and a large sales force built up through the NuVasive combination. Those strengths face pressure from hospital capital budgets, reimbursement trends, and larger rivals such as Stryker and Medtronic that compete across the same procedures.
Investor Outlook
Globus Medical, Inc. (GMED) carries a Weiss Rating of C+ (Hold), and today's decline reflects sector anxiety more than any deterioration in the company's own results. The key test arrives with Q3 results on November 5. Investors should watch whether revenue keeps pace with the $3.18 billion–$3.22 billion full-year guidance, and whether management holds the raised $4.95–$5.05 adjusted-EPS range in light of Stryker's softer outlook. See full rankings of all C+ rated Health Care stocks inside the Weiss Stock Screener.
--